Lamellar Biomedical, led by CEO Alec McLean, develops a pipeline of novel patent-protected medical devices and pharmaceuticals. Its core products include Lamelleye for Dry Eye Disease (DED), Visco-ease for Radiotherapy-Induced Xerostomia (RIX), and Muco-ease for Cystic Fibrosis (CF). The company uses a LAMELLASOME[TM] platform to target indications with high unmet medical need, including infection. Lamellar raised £5.75m in Series C equity funding to support its development and commercialization plans. The funds will be used to commercialize Lamelleye and Visco-ease globally through partners, generate clinical data for Muco-ease to position it for potential co-development, and expand the LAMELLASOME-based pharmaceutical pipeline.

Total raised

$7M

Funding rounds

1

Latest round

Series C

Latest activity

May 2017